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Background. An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. 
The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.
Methods. Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between 
July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were in-
cluded. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard 
regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for weight increases >10% from baseline.
Results. A total of 713 participants, 25.3% women and 91% Caucasian, were included. Of these, 195 (27.4%) started DTG as 
their first ART regimen, whereas 518 (72.6%) were ART-experienced. DTG was associated with abacavir/lamivudine in 326 partici-
pants, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine 
in 75, and tenofovir alafenamide (TAF)/FTC in 59. At 6 and 12 months, weight gain was highest among PWH on TDF/FTC+DTG 
and TAF/FTC+DTG. Baseline CD4 <200 cells/mm3 (HR, 1.84; 95% CI, 1.15 to 2.96), being ART-naïve (HR, 2.24; 95% CI, 1.24 to 
4.18), and treatment with TDF/FTC+DTG (HR, 1.92; 95% CI, 1.23 to 2.98) or TAF/FTC+DTG (HR, 3.80; 95% CI, 1.75 to 8.23) were 
associated with weight gain >10% from baseline. Higher weight (HR, 0.97 by 1 kg; 95% CI, 0.96 to 0.99) and female gender (HR, 0.54; 
95% CI, 0.33 to 0.88) were protective against weight gain.
Conclusions. Naïve PWH with lower CD4 counts and those on TAF/FTC or TDF/FTC backbones were at higher risk of weight 
increase in the course of DTG-based ART.
Keywords.  dolutegravir; HIV metabolic complications; TAF; TDF; weight gain.
The antiretroviral agents currently recommended for the treat-
ment of HIV are all characterized by high efficacy and safety 
[1–3]. In particular, integrase inhibitors (INSTIs) constitute 
the preferred anchor drugs in modern first-line antiretroviral 
therapy (ART), thanks to their demonstrated durable virologic 
efficacy [4], and are characterized by a low rate of adverse events 
[5] and a favorable metabolic profile in lipids compared with 
protease inhibitors (PIs) and efavirenz [6–8]. INSTI, together 
with rilpivirine and doravirine, is the drug recommended for 
treating people with HIV (PWH) with high cardiovascular risk 
[4]. However, a new side effect has emerged in recent years, af-
fecting the class of INSTIs in general and dolutegrvir (DTG) in 
particular, namely an unexpected excess in weight gain during 
the course of treatment [9–12]. The impact of this effect on 
metabolic and cardiovascular outcomes is still unclear at this 
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time [11], sparking a heated debate between those who attribute 
weight gain to a return-to-health phenomenon and those who 
interpret it as an undesired side effect that could influence car-
diovascular risk. Although the mechanisms underlying weight 
gain still remain unclear, the main characteristics of PWH 
gaining weight have been previously reported to be lower CD4 
T-cell count [13–16], higher HIV-RNA [13, 15], low baseline 
body mass index (BMI) [14], female sex [13, 15, 16] and older 
age [13, 14]. Regarding the association between weight gain and 
specific drugs, many studies have highlighted a role of DTG that 
is more evident in ART-naïve PWH [11, 13, 15] and less con-
sistent in ART-experienced PWH [14, 17, 18]. However, DTG 
is usually administered in combination regimens that include 
other antiretrovirals, whose role in weight gain has been poorly 
studied and is not well understood. Backbones such as abacavir/
lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/
FTC) seem to have a neutral effect on weight, BMI, and lean 
body mass changes according to 1 previous study [19], but, on 
the other hand, a significant role of tenofovir alafenamide (TAF) 
over TDF has been reported for weight increase [13, 15, 20]. 
The aim of the present study was to describe the weight changes 
in both naïve and experienced PWH, all treated with DTG, in 
a large prospective cohort and explore the role of the different 
antiretrovirals used in combination with DTG in weight gain. 
Secondary aims were clarifying if weight gain is associated with 
changes in lipids and fasting glucose and describing incident 
obesity and metabolic syndrome among PWH receiving DTG-
based therapies.
METHODS
We analyzed data from the Surveillance Cohort Long-Term 
Toxicity Antiretrovirals (SCOLTA) prospective database. The 
SCOLTA project is a multicenter observational study that started 
in 2002 and that prospectively follows PWH who start to take 
new antiretroviral drugs, with the aim of identifying toxicities 
and adverse events in a real-life setting [21]. Both ART-naïve 
and -experienced PWH can be included in SCOLTA if they are 
aged >18 years and agree to enter the study. Clinical data col-
lected include sex, age, ethnicity, weight, height, and history of 
previous ART. Laboratory data include HIV-RNA, CD4 T-cell 
count, CD4/CD8 ratio, total cholesterol (TC), high-density lip-
oprotein cholesterol (HDL), triglycerides (TGs), and fasting 
glucose and are prospectively collected in anonymous form in a 
central database every 6 months.
We performed a query to this prospectively collected da-
tabase including participants on DTG enrolled from July 
2014 until December 2019 (date of last extraction) for whom 
weight was registered at baseline (time of initiating DTG) 
and who had at least 1 follow-up. Female PWH who became 
pregnant during the study period were excluded. Moreover, 
we did not consider ART combinations that were used in 
≤10 cases. Comparisons of patient demographics and base-
line characteristics among different groups of backbones as-
sociated with DTG were performed using the chi-square test, 
analysis of variance, and the Mann-Whitney U test. Weight 
change from baseline was assessed using a paired t test in the 
univariate analysis at 6, 12, 18, and 24 months of follow-up. 
Overall weight change across follow-up visits (from baseline 
to month 24) was analyzed using a mixed model for repeated 
measures. We compared weight change among backbone 
groups, including potential confounders (differences between 
treatment groups or associated with baseline weight). Active 
hepatitis C virus (HCV) infection and statin use were updated 
over time. If weight was not measured at a follow-up visit, we 
imputed the missing value as the mean of the previous and the 
following visits.
Moreover, with the aim of identifying the factors associated 
with clinically significant weight gain, we defined as weight 
gainers (WGs) as those participants whose weight increased by 
at least 10% from baseline [15]. The associations among ART 
regimens, participant characteristics, and being WGs were 
evaluated with hazard ratios (HRs) and 95% confidence inter-
vals (CIs) using a Cox proportional hazard regression model; 
time was calculated as days between starting a DTG-including 
regimen and the visit where the ≥10% increase was measured. 
Variables included in the model were age, sex, baseline weight, 
risk factor for HIV acquisition, baseline CD4 and Centers for 
Disease Control and Prevention (CDC) stage, naïve status, ART 
duration (set at 0 for naïve participants), statin use, HCV eradi-
cation during the first year of study, and type of DTG-including 
regimen.
The impact of weight gain on lipids and glucose metabolism 
was explored by comparing TC, HDL, TC/HDL ratio, TG, and 
fasting glucose changes at 6 and 12  months between partici-
pants whose weight increased by at least 10% in the first year 
and those whose weight did not, using a general linear model 
including potential confounders. For this analysis, participants 
with weight gain ranging from >1% to <10% in the first year 
of observation were excluded. Participants whose weight in-
creased ≤1% or decreased were defined as nongainers (NGs). 
We also evaluated the frequency of incident obesity and met-
abolic syndrome. Obesity was defined by a body mass index 
(BMI) >30  kg/m2, while metabolic syndrome was defined by 
the presence of central obesity (assumed in PWH with BMI 
>30 kg/m2) and any 2 of the following factors: (1) TG ≥150 mg/
dL or treatment for hypertriglyceridemia; (2) HDL <40 mg/dL 
for males or <50 mg/dL for females or specific treatment for this 
lipid abnormality; (3) raised blood pressure, with systolic blood 
pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg 
or treatment for previously diagnosed hypertension; (4) fasting 
glucose ≥100  mg/dL or diagnosis of type 2 diabetes [22, 23]. 
The study protocol of the SCOLTA group was approved by 
local ethical committees and conducted in accordance with the 
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ethical principles stated in the Declaration of Helsinki. Written 
consent was obtained from all participants.
RESULTS
At the time of this analysis (December 2019), 987 PWH were 
enrolled in the SCOLTA cohort and on treatment with a DTG-
containing regimen. Seven hundred sixty-six met the selection 
criteria for this analysis: weight available at baseline and at 
6-month follow-up. Among these, 53 received a regimen used 
in <10 cases and were excluded.
Characteristics of the Study Population
A total of 713 participants (mean age [SD, range], 47.2 [11.6, 
19–81] years) were included in the present analysis. Women 
represented 25.3% of the sample (n  =  180, of whom 2 were 
transgender women), and 648 participants were Caucasian 
(90.9%); 22.3% were in CDC stage C (n = 159). One hundred 
ninety-five (27.4%) started DTG as their first ART regimen, 
whereas the remaining 518 (72.6%) were ART-experienced 
PWH who switched to DTG after a median (interquartile range 
[IQR]) of 9.8 (4.3–17.4) years of previous ART. DTG was as-
sociated with ABC/3TC in 326 participants (45.7%), TDF/FTC 
in 148 (20.8%), atazanavir or darunavir (boosted with ritonavir 
or cobicistat) in 60 (8.4%), rilpivirine in 45 (6.3%), 3TC in 75 
(10.5%), and TAF/FTC in 59 (8.3%). Mean baseline weight 
(SD) was 69.2 (12.8) kg in naïve and 71.0 (13.6) kg in experi-
enced participants. Further characterization of the study pop-
ulation is given in Table 1. Participants in different groups of 
treatment were different in terms of age, risk factor for HIV 
acquisition, naïve status, initial CD4 T-cell count and CD4/
CD8 ratio, and active HCV infection. Among ART-experienced 
participants, a difference also existed in terms of detectable 
HIV-RNA at baseline and years of ART before DTG treatment. 
Among the participants, 535, 407, and 332 reached 12-, 18-, and 
24-month follow-up. The median observation time (IQR) was 
28 (11–39) months.
Weight Gain in Different ART Regimens
At baseline, women, participants in CDC stage C, and those 
with active HCV infection had significantly lower weight, 
whereas participants on statins were heavier than those not on 
statins. These findings were consistent in naïve and experienced 
participants, even if in some cases the probability for these com-
parisons was higher than the value set for significance (<.05) 
because of the loss of power due to subgroup analysis. The 
mean weights of the participants in different DTG-based regi-
mens at baseline and during follow-up are shown in Figure 1. At 
6 and 12 months, the mean weight change from baseline (± SE) 
was +0.6 ± 0.1 kg (P = .0005) and +1.2 ± 0.2 kg (P < .0001), re-
spectively, in the whole study population; the same figures were 
+1.2 ± 0.3 kg (P < .0001) and +2.4 ± 0.4 kg (P < .0001) in naïve 
and +0.4 ± 0.2 kg (P = .02) and +0.9 ± 0.2 kg (P < .0001) in expe-
rienced participants. Weight over time was analyzed including 
age, sex, risk factor for HIV acquisition, CD4 at baseline, naïve 
status, CDC stage C, updated statin use, and DTG-including 
ART. We found that weight significantly increased and that 
naïve status (P = .002) and type of ART regimen (P = .033) af-
fected weight gain over time. Table 2 shows the mean change 
from baseline by ART regimen: at 6-month follow-up, weight 
increased significantly in participants on RPV+DTG, PI+DTG, 
TDF/FTC+DTG, and TAF/FTC+DTG. After adjusting for age, 
sex, baseline weight and CD4, naïve status, CDC stage, statin 
use (use at enrollment and 1-year updated information), and 
active HCV infection (at enrollment and 1-year updated in-
formation), weight increase was confirmed to be significant at 
6-month follow-up; further increases at 12-month follow-up 
were only significant for TDF/FTC+DTG and TAF/FTC+DTG. 
In the same model, using 3TC/ABC+DTG as the reference, 
weight change was significantly higher in the TDF/FTC+DTG 
(P = .004) and PI+DTG groups (P = .02) at 6-month follow-up. 
However, in subsequent follow-up, no difference was observed.
Factors Associated With Weight Gain
According to our definition, 75 participants (10.5%) became 
WGs during the whole observation period. In multivariate Cox 
regression (Table 3), higher baseline weight and female sex rep-
resented factors that were protective against becoming a WG. 
Baseline CD4  <200 cells/mm3 and being ART-naïve were as-
sociated with higher weight change from baseline. Eradication 
of HCV infection was suggested as a risk factor, although of 
borderline significance. With regard to regimens, we used the 
most used regimen, 3TC/ABC+DTG, as the reference cat-
egory: HRs were higher for all the remaining regimens, but 
only significantly so for TDF/FTC+DTG and TAF/FTC+DTG 
(Table 3). The analysis of factors associated with weight gain in 
patients who were ART-naïve or -experienced is available in the 
Supplementary Data.
Impact of Weight Gain on Lipids and Blood Glucose
To explore the possible effect of weight gain on blood lipids and 
glucose, we compared TC, HDL, TG, and fasting glucose be-
tween 12-month WG and NG participants. One hundred five 
(14.7%) participants with intermediate weight gain were ex-
cluded from this analysis. Thus, we compared 49 WGs vs 526 
NGs. The trends of TC, HDL, TG, and fasting glycemia during 
the study period are shown in Table  4. Controlling for age, 
sex, statin use, and regimen, all these values were not signifi-
cantly different by weight gain, except for HDL variation, which 
showed a higher increase in WG participants (P = .04).
Obesity and Metabolic Syndrome
Out of 608 participants with available baseline BMI, 46 
(7.6%) were obese and 186 (30.6%) were overweight. Among 
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overweight participants, 15 (8.1%) crossed the threshold for the 
obesity definition, and 37 (19.9%) lost enough weight to be-
come normal weight.
At baseline, among 464 (65.1%) participants with complete 
data for metabolic syndrome evaluation, 26 (5.6%) had met-
abolic syndrome. Out of 438 without baseline metabolic syn-
drome, 10 developed it during follow-up, resulting in a rate of 
9.9 cases per 1000 person-years (95% CI, 5.0 to 17.7).
DISCUSSION
In this work, we described the weight changes in one of the lar-
gest cohorts of DTG-treated PWH prospectively followed up in 
a real-life context. Similar to previous data, we confirmed that 
PWH gained weight during DTG treatment, especially if naïve 
to ART [11, 14, 17]. We also found that people treated with DTG 
in association with TAF/FTC or TDF/FTC were more prone to 
experience the weight increase. A possible role of TAF has been 
previously observed in ART-naïve and -experienced PWH [13, 
15, 20, 24] and was confirmed in our work in a real-life con-
text, where TAF was mainly used to treat ART-naïve partici-
pants and, despite low numbers, seemed to be linked to nearly 
4-fold higher risk of weight gain compared with ABC/3TC + 
DTG. The reasons underlying this observation remain unclear, 
despite a possible effect on lipid metabolism having been previ-
ously observed for TAF that might in some way also influence 
fat accumulation [25, 26]. It is also possible that the inverse cor-
relation, namely the accumulation of fat during TAF treatment, 
could be one of the reasons for the elevation of lipid levels that 
has been observed in the course of TAF treatment. In fact, in 
the general population, a correlation between visceral fat and 
higher levels of TG and TC exists, as omental and mesenteric 
fat play an important role in the hepatic lipid metabolism, 
contributing to hypertriglyceridemia and low HDL concen-
trations [27]. However, due to the recent introduction of TAF 
in clinical practice, observational data are still scarce [24], and 
more studies will be needed to identify the potential metabolic 
pathway by which TAF could interfere with fat accumulation 
or blood lipid metabolism. Moreover, we did not observe dif-
ferent effects on lipids between WGs and NGs, or participants 
treated with TDF, a drug considered to have a neutral effect on 
lipids [28], who experienced nearly double the risk of weight 
gain compared with those on ABC/3TC in SCOLTA. The ef-
fect of TDF/FTC on weight has been studied in the past, but 
the results were not univocal. No effect was found in previous 
studies in naïve [15, 19] or experienced PWH [18], but in a re-
cently published pooled analysis of 8 randomized controlled 
clinical trials of treatment-naïve PWH initiating ART between 
2003 and 2015, Sax et al. showed that PWH treated with TDF 
gained more weight compared with those treated with AZT 














3TC + DTG RPV + DTG PI + DTG
Baseline 6-mo 12-mo 18-mo 24-mo
3TC/ABC + DTG TDF/FTC + DTG TAF/FTC + DTG
Figure 1. Weight by regimen. Mean weight (kg) at baseline and 6-month, 12-month, 18-month, and 24-month follow-up in people treated with different dolutegravir-
containing regimens. Dolutegravir was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine in 148, boosted protease in-
hibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide/emtricitabine in 59. Abbreviations: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; FTC, 
emtricitabine; PI, protease inhibitor; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide.
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[15]. Then, according to our results, tenofovir could influence 
weight gain in both its prodrug forms, TDF and TAF, but on the 
contrary, previous studies have found that PWH on ABC/3TC 
gained more weight than those on tenofovir [9, 29], whereas 
in other studies both ABC/3TC and TDF/FTC had a neutral 
effect on weight, BMI, and lean body mass changes [15, 19]. 
The discordant results of the abovementioned studies might 
reside in different patient populations and unmeasured con-
founding factors; dietary, psychological, social, and economic 
factors can play a role. Moreover, it is possible that not only the 
single drugs, but also their association could increase the risk 
of gaining weight, although with an unknown mechanism, or 
simply enhancing the effect of DTG in certain combinations.
Last, but not least, HIV infection itself and the virus activity 
may also play a role in weight changes. In our study, ART-naïve 
PWH and those with the lowest CD4 T-cell counts were at 
higher risk of gaining weight, supporting the hypothesis that 
weight gain might be explained, at least in part, as a “return to 
health” phenomenon, the result of successfully suppressing viral 
replication, controlling inflammation, and normalizing resting 
energy expenditure [30]. Of note, in healthy HIV-uninfected 
males, weight did not change with use of either TDF/FTC or 
cabotegravir [31, 32].
We also found higher risk of being a WG for male PWH. This 
is in contrast with literature data collected in PWH [9, 13, 15], 
where black females especially were at higher risk. However, 
in our study, participants were mainly Caucasian, and women 
were little represented. The difference in country of origin and 
ethnicity might indeed play a role in the evaluation of weight 
gain and gender differences, as in developed countries more 
men than women are overweight and obese, whereas in devel-
oping countries overweight and obesity are more prevalent in 
women [33]. Moreover, in the general population living in de-
veloped countries, overweight and obesity are expected to peak 
in men at about 55 years of age, different from women, in whom 
the peak is expected at a slightly older age, closer to 60 years 
[33]. PWH enrolled in the present study, mainly male and about 
50 years old, might be more representative of the general pop-
ulation of developed countries than PWH enrolled in previous 
studies; our findings may be similar to the recently presented 
data from the Swiss cohort, where male PWH were shown to be 
at greater risk of weight gain than women [34].
Finally, we found that the incidence of MS was about 10 
cases per 1000 person-years. A higher prevalence of metabolic 
syndrome in PWH than in the general population has been 
reported in the past [35], with an estimated incidence in devel-
oped countries ranging between 8 and 14 cases per 100 person-
years [36–38]. Although the follow-up was limited in our study, 
we did not find an excess incidence of metabolic syndrome. 
Moreover, blood levels of TC, TC/TG, and fasting glucose did 
not change differently in WGs and NGs in our study, suggesting 
that the metabolic impact of weight gain was low in our cohort.
This study has several potential limitations. First, owing 
to the observational nature of the study, PWH were not ran-
domly assigned to drug therapies, and confounding bias could 
have occurred, based on clinicians’ decisions to prescribe dif-
ferent drug associations in PWH with different baseline char-
acteristics. In addition, dietary habits and personal choices or 
sociopsychological conditions influencing weight loss or gain 
were not recorded. Finally, our ability to detect incident obesity 
and metabolic syndrome might be limited by the lack of com-
plete data to define these events in part of the study population 
and by the relatively short follow-up.
Table 3. Cox Regression Analysis for Weight Gain >10%
Hazard Ratio 95% CI P
Baseline age (by 5 y) 0.97 0.89 1.06 .48
Gender F vs M     
M 1.00    
F 0.54 0.33 0.88 .01
Baseline weight (by 1 kg) 0.97 0.96 0.99 .002
Risk factor for HIV acquisition     
Sexual 1.00    
IVDU 1.23 0.68 2.24 .49
Other 0.94 0.56 1.61 .84
Baseline CD4, cells/mm3     
>500 1.00    
200–500 0.98 0.64 1.52 .94
<200 1.84 1.15 2.96 .01
CDC stage     
A–B 1.00    
C 1.40 0.94 2.10 .10
Status     
ART-experienced 1.00    
ART-naïve 2.24 1.20 4.18 .01
Years of previous  
ART (by 1 y)
0.99 0.96 1.02 .59
Statin use     
Never 1.00    
Since baseline 1.18 0.55 2.55 .67
Started after enrollment 1.37 0.49 3.82 .55
Baseline active HCV     
No 1.00    
Active HCV, untreated 1.23 0.58 2.61 .60
Active HCV, eradicated 1.84 0.92 3.69 .08
ART regimen     
3TC/ABC/DTG 1.00    
3TC + DTG 1.72 0.82 3.61 .15
RPV + DTG 1.37 0.60 3.12 .45
PI + DTG 1.33 0.68 2.57 .40
TDF/FTC + DTG 1.92 1.23 2.98 .004
TAF/FTC + DTG 3.80 1.75 8.23 .0007
The model equation included age, sex, baseline weight, risk factor for HIV acquisition, 
baseline CD4 and CDC stage, naïve status, ART duration (set at 0 for naïve participants), 
statin use, HCV eradication during the first year of study, DTG-including regimen. The 
model for naïve status estimate did not include ART duration.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; CDC, Centers 
for Disease Control and Prevention; CI, confidence interval; DTG, dolutegravir; FTC, 
emtricitabine; HCV, hepatitis C virus; IVDU, intravenous drug use; RPV, rilpivirine; PI, pro-
tease inhibitor (atazanavir, darunavir); TAF, tenofovir alafenamide; TDF, tenofovir disoproxil 
fumarate.
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In conclusion, in our study, naïve PWH and those with lower 
CD4 counts were at higher risk of weight gain, and TAF/FTC 
and TDF/FTC were the drugs that in combination with DTG 
had the highest impact on weight. The real clinical implications 
of weight gain on cardiovascular risk still need to be defined, 
whereas weight gain in people who are not overweight should 
be considered a favorable effect, as it has a demonstrated ben-
efit in terms of mortality [39]. Moreover, weight gain seemed to 
have no impact on fasting glucose or cholesterol levels in our co-
hort, where, despite weight gain, we did not find a high impact 
on incident obesity and MS. The fact that studies with differing 
designs and populations have found different risk factors for 
weight gain in the literature highlights how treatment should 
always be tailored to the individual patient, without falling to 
the temptation of generalizing the study results to all PWH.
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T0 = baseline; T1 = 6 months; T2 = 12 months; T3 = 18 months; T4 = 24 months.
Abbreviations: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; FTC, emtricitabine; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); TAF, tenofovir alafenamide; TDF, tenofovir 
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Table 4. Blood Lipids and Glucose Changes in 548 Nongainers and 49 Weight Gainers
NGs WGs Pa
Total cholesterol, mean ± SD, mg/dL   BL, .04
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At 12 mo 184 ± 42 181 ± 46
HDL cholesterol, mean ± SD, mg/dL   BL, .008
Baseline 47 ± 17 40 ± 13 .046
At 6 mo 48 ± 16 41 ± 13
At 12 mo 49 ± 15 47 ± 15
TC/HDL, median (IQR)   BL, .10
Baseline 4.1 (3.2–5.1) 4.3 (3.8–5.3) .18
At 6 mo 3.9 (3.1–4.9) 4.3 (3.3–5.5)
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Baseline 91 ± 27 90 ± 16 .49
At 6 mo 92 ± 23 92 ± 16
At 12 mo 93 ± 22 93 ± 15
Abbreviations: BL, baseline; HDL, high-density lipoprotein; IQR, interquartile range; NGs, nongainers; TC, total cholesterol; WGs, weight gainers.
aTest for repeated measures, adjusted for age, sex, baseline statin use, regimen type.
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